Expert opinion on emerging drugs

Keyphrases

Publications

2023

Onur Keskin, Cihan Yurdaydin
Emerging drugs for hepatitis D. Expert opinion on emerging drugs (2023)
Sandra Elsheikh, Nicola Tidbury, Gregory Y H Lip
A review of emerging factor XI inhibitors. Expert opinion on emerging drugs (2023)
Ning Dong, Lucia Perez-Lamas, Julio C Chavez
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma. Expert opinion on emerging drugs (2023)
Giuseppe D'Angelo, Mario Ascione, Ilaria Morra, Paolo Verrazzo, Giuseppe Bifulco, Pierluigi Giampaolino, Luigi Della Corte
What's new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II. Expert opinion on emerging drugs (2023)
Andrea Esposito, Paolo Bossi
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials. Expert opinion on emerging drugs (2023)
Rohit K Jain, Avani M Singh, Xuefeng Wang, José A Guevara-Patiño, Guru Sonpavde
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. Expert opinion on emerging drugs (2023)
Nikhil Das, Sameer Chaurasia, Rishi P Singh
A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration. Expert opinion on emerging drugs (2023)
Robert I Fox, Carla M Fox, Sara S McCoy
Emerging treatment for Sjögren's disease: a review of recent phase II and III trials. Expert opinion on emerging drugs (2023)
Onur Keskin, Cihan Yurdaydin
Emerging drugs for hepatitis D. Expert opinion on emerging drugs (2023)
Onur Keskin, Cihan Yurdaydin
Emerging drugs for hepatitis D. Expert opinion on emerging drugs (2023)
Sandra Elsheikh, Nicola Tidbury, Gregory Y H Lip
A Review of Emerging Factor XI inhibitors. Expert opinion on emerging drugs (2023)
Seng Kiong Tan, Mark E Cooper
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease? Expert opinion on emerging drugs (2023)
Rohit K Jain, Avani M Singh, Xuefeng Wang, José A Guevara-Patiño, Guru Sonpavde
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. Expert opinion on emerging drugs (2023)
Ana C Veneziani, Eduardo Gonzalez-Ochoa, Amit M Oza
Emerging peptide therapeutics for the treatment of ovarian cancer. Expert opinion on emerging drugs (2023)
Laura Neurath, Ferdinando D'Amico, Silvio Danese
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert opinion on emerging drugs (2023)
Maxwell J Wagner, Charles P Daniel, Connor J Plaisance, Grant E Borne, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
Apomorphine for Parkinson's disease: pharmacologic and clinical considerations. Expert opinion on emerging drugs (2023)
Renata Ferrarotto, Flavia Bonini, Luana Guimaraes De Sousa
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma. Expert opinion on emerging drugs (2023)
Carmelo Sofia, Alessia Comes, Giacomo Sgalla, Luca Richeldi
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond. Expert opinion on emerging drugs (2023)
Francesca Casaluce, Cesare Gridelli
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly? Expert opinion on emerging drugs (2023)
Howard Trachtman, Radko Komers, Jula Inrig
Status of current trials and potential future trials with sparsentan. Expert opinion on emerging drugs (2023)
Francesca Casaluce, Cesare Gridelli
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly? Expert opinion on emerging drugs (2023)
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, Andrzej Pilc
Potential use of psilocybin drugs in the treatment of depression. Expert opinion on emerging drugs (2023)
Onur Keskin, Cihan Yurdaydin
Emerging drugs for hepatitis D. Expert opinion on emerging drugs (2023)
Alessandro Costa, Emilia Scalzulli, Ida Carmosino, Marcello Capriata, Claudia Ielo, Chiara Masucci, Mauro Passucci, Maurizio Martelli, Massimo Breccia
Systemic mastocytosis: 2023 update on diagnosis and management in adults. Expert opinion on emerging drugs (2023)
Thinzar Min, Stephen C Bain
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials. Expert opinion on emerging drugs (2023)
Laura Neurath, Ferdinando D'Amico, Silvio Danese
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: Review of phase II and III clinical trials. Expert opinion on emerging drugs (2023)
Danica Brister, Mustafaa Wahab, Moaaz Rashad, Nermin Diab, Martin R J Kolb, Imran Satia
Emerging drugs in the treatment of chronic cough. Expert opinion on emerging drugs (2023)
Thinzar Min, Stephen C Bain
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials. Expert opinion on emerging drugs (2023)
Claudio Tana, Francesco Cipollone, Maria Adele Giamberardino, Paolo Martelletti
New drugs targeting calcitonin gene-related peptide for the management of migraines. Expert opinion on emerging drugs (2023)
Robert I Fox, Carla M Fox, Sara S McCoy
Emerging treatment for Sjögren's disease: a review of recent phase II and III trials. Expert opinion on emerging drugs (2023)
Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, Francesca Trojsi, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Expert opinion on emerging drugs (2023)
Silvia Salvatori, Benedetto Neri, Irene Marafini, Mattia Brigida, Giovanni Monteleone
Emerging oral drug options for ulcerative colitis. Expert opinion on emerging drugs (2023)
Darosa Lim, Julianne Kleitsch, Victoria P Werth
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials. Expert opinion on emerging drugs (2023)
Magdalena I Tolea, Reem Ezzeddine, Simone Camacho, James E Galvin
Emerging drugs for dementia with Lewy bodies: A review of Phase II & III trials. Expert opinion on emerging drugs (2023)
Robert I Fox, Carla M Fox, Sara S McCoy
Emerging treatment for Sjögren's disease: a review of recent phase II and III trials. Expert opinion on emerging drugs (2023)
Robert I Fox, Carla M Fox, Sara S McCoy
Emerging treatment for Sjögren's disease: a review of recent phase II and III trials. Expert opinion on emerging drugs (2023)

volume 27, number 4, 2023

Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa. Expert opinion on emerging drugs 27 (4) (2023)

volume 27, number 3, 2022

Isabelle Fajac, Isabelle Sermet-Gaudelus
Emerging medicines to improve the basic defect in cystic fibrosis. Expert opinion on emerging drugs 27 (3) (2022)
Julia Sewell, Andrew Östör
Emerging injectable therapies for osteoarthritis. Expert opinion on emerging drugs 27 (3) (2022)
Zhen Long, Jennifer R Grandis, Daniel E Johnson
Emerging tyrosine kinase inhibitors for head and neck cancer. Expert opinion on emerging drugs 27 (3) (2022)
Udo Rudloff
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Expert opinion on emerging drugs 27 (3) (2022)
Karl-Erik Andersson
Emerging drugs for the treatment of bladder storage dysfunction. Expert opinion on emerging drugs 27 (3) (2022)
Jennifer Hong, Darian Vernon, Jelena Kunovac, Stephen Stahl
Emerging drugs for the treatment of major depressive disorder. Expert opinion on emerging drugs 27 (3) (2022)
Siddharth Bhatt, Rohit Kothari, Durga Madhab Tripathy, Sunmeet Sandhu, Mahsa Babaei, Mohamad Goldust
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials. Expert opinion on emerging drugs 27 (3) (2022)

volume 27, number 4, 2022

Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren
Response: 'letter to the editor: emerging gene therapy products for RPGR -associated X-linked retinitis pigmentosa'. Expert opinion on emerging drugs 27 (4) (2022)
Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren
Response: 'letter to the editor: emerging gene therapy products for RPGR -associated X-linked retinitis pigmentosa'. Expert opinion on emerging drugs 27 (4) (2022)
Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa. Expert opinion on emerging drugs 27 (4) (2022)
Anastasios Georgiadis, Alexander J Smith, Michel Michaelides, Stuart Naylor, Alexandria Forbes
Letter to the editor: 'Emerging gene therapy products for RPGR -associated X-linked retinitis pigmentosa'. Expert opinion on emerging drugs 27 (4) (2022)
Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa. Expert opinion on emerging drugs 27 (4) (2022)
Anastasios Georgiadis, Alexander J Smith, Michel Michaelides, Stuart Naylor, Alexandria Forbes
Letter to the editor: 'Emerging gene therapy products for RPGR -associated X-linked retinitis pigmentosa'. Expert opinion on emerging drugs 27 (4) (2022)